SOURCE: Alexium International Group

Alexium International Group

October 16, 2015 14:14 ET

Alexiflam Chemistry Expands to Second Major Bedding Brand

PERTH, AUSTRALIA and GREER, SC--(Marketwired - Oct 16, 2015) -  Alexium International Group Limited (Alexium) (ASX: AJX) (AX: AJX) (OTCQX: AXXIY) is pleased to announce that based on the fire retardancy (FR) performance, environmental friendly formulation and value proposition of our Alexiflam™ chemistry, our major bedding client (for more details see press release on 14 September 2015) has expanded the use of our Alexiflam™ treatments to a second US national bedding brand under its corporate umbrella.

Total annual revenue to Alexium from these two US national bedding brands is expected to be $5M USD ($6.8M AUD) pa, with revenue from this second brand to commence before the end of 2015. For customer marketing confidentiality reasons, the brand details will not be provided until products are in store.

Dirk Van Hyning, President of Alexium, stated, "This second US national major brand is strong reinforcement of not just the value Alexium chemistries bring to the bedding market, but their ease of use, as this second program was developed proactively by our customer with limited involvement from Alexium staff. We anticipate our presence in this market segment will continue to grow from this solid foundation."

About Alexium
Alexium International Group Limited (ASX: AJX, AX:AJX OTC QX: AXXIY) holds proprietary patent applications for a process developed initially by the U.S. Department of Defense, which allows for the surface modification and attachment of nano-particles or multiple chemical functional groups to surfaces or substrates to provide functions such as fire retardancy, water proofing, oil proofing, and anti-microbial treatments. Applications under development include but are not limited to textiles, paints, and packaging, glass and building materials. Alexium's fire retardant chemical treatment are currently marketed for different fabric markets under the Ascalon™, Nycolon™, Nuvalon™, and Polytron™, Omnitron™, Bactron™ and Alexiflam™ trademarks.

Contact Information

  • U.S. Contacts:
    Nick Clark
    Chief Executive Officer
    U.S.: +1 864.991.6687

    Bradi Dobson
    Marketing Specialist

    U.S. R&D Center:
    8 Distribution Court
    Greer, SC 29650
    T: +1 864.416.1060
    F: +1 864.752.6465

    U.S. Corporate Office:
    148 Milestone Way
    Greenville, SC 29615
    T: +1 864.603.1165
    F: +1 864.752.6465

    Matt Wright
    Investor Relations
    AUS: +61 451.896.420

    ABN: 91 064 820 408
    ASX: AJX